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1. Introduction
In brief, adult stem cells (SCs) give rise to repopulation (engraftment) of recipient's bone
marrow  (BM)  followed  by  complete  and  long-term  reconstitution  of  hematopoiesis.  In
addition,  totipotent  SCs are  also  capable  of  colonizing different  tissues  (homing).  Initial
studies  showed that  "implantation"  of  autologous  SCs  into  damaged and ischemic  area
induces their  homing and subsequent "transdifferentiation" into the cell  lineages of  host
organ,  including collateral  vessel  formation.  Angiogenesis  growth factors – or genes en‐
coding  these  proteins  –  promote  the  development  of  collateral  micro-angiogenesis  or
"therapeutic neovascularization" [1– 5].
Generally, SC transplant involves the administration of high-dose chemotherapy (condition‐
ing regimen) and (re)infusion of collected cells in order to obtain an abolition of disease, as
well as to get hematopoietic reconstitution and clinical improvement of patient. SC transplant
with reduced-intensity conditioning (RIC) can be offered to patients who are ineligible for
high-dose conditioning because of their age or comorbidities [2]. Hematological diseases have
so far been the most common indication of this treatment modality; it has been less often used
for nonmalignant disorders. Nowadays BM and peripheral blood (PB) derived SC transplants
are more common in adult allogeneic or autologous setting [2, 6– 8]. Umbilical cord blood
(UCB) transplants have provided hopeful results in pediatric setting mainly when a matched
unrelated SC donor is not obtainable [9–12].
In clinical practice, SCs can be collected by: (a) multiple aspirations from BM; (b) harvesting
PB after mobilization with chemotherapy and/or growth factors (rHuG-CSF), and (c) by
specific processing from UCB. SCs collected from the stated sources can be clinically applied
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(transplanted) immediately following harvesting (allogeneic setting) or after a long-term
storage in frozen state – cryopreservation (autologous setting) [2].
2. Stem cell transplants – A short chronological consideration
Independent SC-researchers recognized that all blood cells originate from one primitive BM
cells (totipotent SC) located in marrow – space where the entire hematopoiesis takes place.
Initial animal studies revealed that the BM was the organ most sensitive to the damaging effect
of gamma irradiation [2]. Quickly, it became clear that (re)infusion of marrow cells or SCs could
rescue lethally irradiated animals. Thomas with colleagues started on, and after that optimized
(for this initial period) the BM transplant (BMT) program for humans and published in 1957
the first clinical results [13]. During the late 1950s have been also described the first syngeneic
BMT in patients with leukemia [14]. Mathe and coworkers published the treatment of patients
by allogeneic SC transplant after of accidental irradiation [15]. These transplants were
performed before the discovery of major histocompatibility (MCH) system. In addition, it is
not excluded that the observed recovery of some patients were a result of the recovery of
autologous hematopoietic system [16]. The first successful BMT (allogeneic) was performed
on a child with severe combined immunodeficiency disease (SCID). Cells were collected from
his sister, and his immune system was restored following transplant [2]. However, in most
cases transplants in humans have been unsuccessful (because of the graft rejection or expansion
of the Graft versus Host Disease – GvHD).
The modern era of SC transplants – as a standard therapy – started with fundamental discovery
and permanent progress in the knowledge of MHC, that is human leukocyte antigen (HLA)
system [17]. These antigens give the body's immune system the ability to determine what
belongs and what does not belong to the human body. Whenever the immune system does
not recognize antigens expressed on a cell surface, it produces antibodies and other mediators
to destroy the cells with non-recognizable antigens. In order for BMT to work, the recipient's
immune system must not try to destroy the donated cells. This comprises that the HLA antigens
on the donated SCs have to be identical or extremely similar to the antigens of the recipient's
cells. Even with this careful HLA matching, transplant may still fail because recipient's immune
system destroys transplanted cells (graft rejection) or donor's cells attempt to damage recipi‐
ent's target cells (GvHD) [2]. Thomas and coworkers almost immediately published positive
results of the first allogeneic BMT in patients with hematologic malignancies – using cells from
donors selected on the basis of the HLA system [18]. After all, Thomas ED was awarded the
Nobel prize in medicine (1990) for his overall pioneering work on BMT topic. He was awarded
the prize because of his numerous triumphant activities in both, experimental and clinical
transplant setting.
In addition to marrow, PB has gained popularity as a SC source since their initial introduction
in the early 1980s [19]. Over the past decades, the use of these transplants has expanded rapidly
[6– 8]. Using umbilical cord blood (UCB) derived SCs, successful transplant occurred the first
time in the treatment of Fanconi anemia and other disorders later than [9–12]. It is known that
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only about one-third of patients have related HLA-matched donor. For that reason, some
sources of allogeneic donors – including unrelated HLA-compatible individuals, have to be
considered as the possible alternative. As a result, National Marrow Donor Program’s
registries of volunteer donors has been created and data accumulated by organizing a unique
database for potential donors (Bone Marrow Donors Worldwide – BMDW) [20].
The late 1990s brought a new apprehension regarding the biology and related novel clinical
potential of SCs. Researchers began to realize that manipulation of adult animal tissues could
sometimes yield previously unsuspected cell types; for example, that some BM derived SCs
could be turned into cardiomyocytes, hepatocytes or nerve and other somatic cells – phenom‐
enon known as the SC "plasticity". Finally, using SC plasticity, cell–based therapies for
treatment of the ischemic heart diseases started through beginning of the new millennium and
currently are in an expansion phase in the other fields of regenerative medicine [21–30].
3. Adult stem cells: New concepts in phenotypes and functionality
To prove that SCs derived from BM and PB, including hematopoietic SCs, are indeed trans‐
differented or transformed into solid organ specific cells, several conditions must be met:
• The origin of the exogenous cell integrated into solid-organ time must be documented by
marking the cell, preferably at the single-cell level;
• Cell should be processed with a minimum of ex vivo manipulation which may make them
more susceptible to crossing lineages;
• The exogenous cells must be shown to have become an integral morphological part of the
newly acquired tissue;
• Transdifferented cells must have shown to acquire the function of the particular organ into
which it has been integrated both, by expressing organ-specific proteins and by showing
specific organ function.
Nevertheless, taking into consideration their common features described in the literature, it is
very likely that various investigators have described overlapping populations of develop‐
mentally early SCs that are closely related. Our intention is to make a clear distinction between
three different types of adult SCs.
4. The concept of hematopoietic stem cells
Organ/tissue specific niche (like in BM, liver, etc) exists as a deposit (storage) of the adult SCs
in a specific location [31]. These cells are circulating in a very low number in the PB. Accumu‐
lating evidence suggests that SCs may also actively migrate/circulate in the postnatal period
of life. SC trafficking/circulation may be one of the crucial mechanisms that maintains the pool
of SCs dispersed in SC-niches of the same tissue, that are spread throughout different ana‐
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tomical areas of the body. This phenomenon is very well described for hematopoietic SCs
(HSCs), but other, already tissue committed SC or TCSC (for example, endothelial, skeletal
muscle or neural SCs) are probably circulating as well. BM is the home of migrating SCs with
not only HSCs within their niches, but also a small number of TCSC, which might be the reason
why many authors think that HSC may transdifferentiate, although we do not have a direct
proof for that. They might have plasticity, but not necessarily the "potential for transdifferen‐
tion" [32–39]. What is differentiated in the tissue of injection might be TCSC characteristic for
that tissue. It has been shown that number of these cells is decreased with ageing (long living
and short living mice and humans). It would be interesting to identify genes that are respon‐
sible for tissue distribution/expansion of TCSC. These genes could be involved in controlling
the life length of the mammals.
Therefore, BM derived SCs are a heterogeneous population of cells with HSC and TCSC,
the morphological  and functional  characteristics  of  which are different  from HSC. Their
number among mononuclear cells (MNCs) is very low (approximately one cell per 1 000
–  10  000  marrow MNCs)  within  young  mammals  and  might  play  a  role  in  healing  of
small injuries [31, 32].
In severe injuries (like hart infarct or stroke) they have no possibility to reveal their full
therapeutic potential. The allocation of these cells to the damaged areas depends on homing
signals that maybe inefficient in the presence of some other cytokines or proteolytic enzymes
that are released from damaged tissue associated leukocytes and macrophages. We can
envision, for example that metalloproteinases released from inflammatory cells may degrade
SDF-1 locally, and thus perturb homing of CXCR4+ TCSC. There is possibility that these cells
while "trapped" in BM are still in: "latent stage" – not fully functional and need the appropriate
activation signals by up till now unknown factors [32–37].
These cells also, at least in some cases could be attracted to the inflammatory areas, and
if not properly incorporated into the damaged tissue they may transform and initiate tu‐
mor growth. Briefly, between the pools of TCSCs, there are probably those already com‐
mitted  to  transdifferentiate  into  neural  cells,  or  cells  of  tissues  and  organs  other  ten
neural,  but  we still  do not  have the  control  over  their  tracking,  homing and finally  re‐
generative capacity in the given tissue,  which is  a fundamental prerequisite for success‐
ful regenerative therapy.
5. The concept of "very small embryonic-like" stem cells
In a discovery that has the potential to change the face of SC research, a University of Louisville
scientist has identified cells in the adult body that seem to behave like embryonic SCs [38, 40–
44]. The cells, drawn from adult BM, look like embryonic SCs and appear to mimic their ability
to multiply and develop into other kinds of cells. The finding, presented the first time at the
47th Annual Meeting of the American Society of Hematology (ASH), was announced at the
society's news conference. A study by Ratajczak's team published in the journal "Leukemia"
was the first to identify a type of SC in adult marrow that acts differently than other BM derived
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SCs [38]. The newly identified cells – called "Very Small Embryonic-Like" (VSEL) SCs – have
basically the same ultrastructure and protein markers as embryonic SCs [38]. Ratajczak and
several other researchers from mentioned ASH meeting showed that VSEL SCs mobilize into
the blood stream to help repair damaged tissue following a stroke [37]. In further research
advance, Ratajczak's team also has grown VSEL cells in a lab and has stimulated them to change
into nerve, heart and pancreas cells [40–42]. The differences in ultrastructure between HSC
and VSELs are shown in Figure 1.
(For picture thanks to kind permission of M. Ratajczak)
Figure 1. Ultra-structural differences between mouse VSEL and HSC
Along with this new concept, there is a premise that in regenerative therapy done before, with
HSCs (considered to have plasticity and multipotency) the VSELs were "contaminants" that
actually contributed to positive regenerative clinical outcome, since they have those capabili‐
ties. This is an interesting concept which should be seriously considered in humans. However,
since VSELs have been found in human UCB and BM first [37], and then used and applied
with the patients [43–44] they seem to be of a critical importance for consideration of SC
transplant choice based upon the phenotype and number of SCs aimed to be transplanted
within a given clinical scenario.
6. The concept of mesenchymal stem cell – with dental pulp cells as an
example
Many human tissues are the source of SCs responsible for tissue development and regenera‐
tion. Beside marrow (Bone Marrow Stromal Stem Cells – BMSCs), currently it is considered
that dental pulp is practically the most approachable and the most important source of adult
mesenchymal SCs [45–47] (Figure 2).
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(With courtesy of V. Todorovic)
Figure 2. Mesenchymal stem cells
Within the last decade, several populations of SCs from dental pulp were isolated and
characterized: a) Dental Pulp Stem Cells – DPSC; b) cells from Human Exfoliated Decidual
teeth – SHED; and c) Immature Dental Pulp Cells – IDPC [46, 47]. These cells are of the
ectomesenchymal origin, located in perivascular niche, highly proliferative, clonogenic,
multipotent and similar to BMSCs. Within in vitro conditions, they can differentiate with
certain intercellular differences toward odontoblasts, hondrocytes, osteoblasts, adipocytes,
neuron/glial cells, smooth and skeletal muscle cells. Within in vivo conditions (after implan‐
tation) they show different potential for dentine formation, as well as osteogenesis; after
transplant in mouse with compromised immune system, they make good grafts in different
tissues, and are capable of migrating into the brain, where they survive a certain time while
reaching neurogenic phenotype. DPSCs have immunomodulatory effect, as they can be
involved into immune response during infection of dental pulp by NF-kB activation and by
inhibiting T-cell proliferation, suggesting their immunosuppressive effect [47].
The future research should give us the complex data on the molecular and functional charac‐
teristics of dental pulp SCs, as well as differences between various populations of these cells.
Such research would fundamentally contribute to the better knowledge on the dental pulp
SCs, which is necessary due to their potential clinical application in in vivo cell transplant, tissue
engineering, and gene therapy (in vivo or ex vivo). Actually, by the isolation of IDPCs, which
are the most primitive, but also the most plastic (similar to embryonic SCs) they are opening
the new perspectives in a potential therapeutic application of these cells not only in regener‐
ation of dentine, otherwise also the regeneration of periodontal and "bone-junction" tissue of
craniofacial region, as well as in the therapy of neurotrauma, myocardial infarction and other
tissue damages [46, 47].
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7. Stem cell harvesting and ex vivo manipulation
For therapeutic use, SCs can be collected by: a) multiple aspirations from BM; b) harvesting
from PB after mobilization (chemotherapy and/or growth factors – rHuG-CSF); and c)
collection from UCB. Collected cells can be clinically applied (transplanted) immediately
following harvesting (allogeneic setting) or after storage in frozen state or cryopreservation
(autologous setting).
8. Bone marrow derived stem cells
Historically, BM was the first SC source for transplants. Cells were collected by multiple aspira‐
tions from the iliac crests, under sterile conditions, while the donor was generally anesthetized.
The target volume of collected BM aspirate is 10 – 15 mL per kg of donor body mass (kgbm). In
order to provide required number of total nucleated cells (TNCs) – that is TNC ≥ 3x108/kgbm –
around 200 aspirations are required (single aspirate volume = 2 – 5 mL) (Figure 3).
Figure 3. Stem cell collection from bone marrow
After collection, BM aspirate should be filtered in order to remove bone and lipid particles and
cell aggregates. Anticoagulation is created using citrate solution and by using of the heparin
diluted in saline (5 000 IU/500 mL) [2, 48–50].
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BM aspirate volume – precisely red blood cell count or plasma quantity – reduction is required
(processing), especially for ABO incompatible transplants. Depletion of T-cells in cell suspen‐
sion is achieved using ex vivo purging (by immunomagnetic technique). These SC purification
procedures (processing and purging) enable reduction of red cell for around 80 – 90% and
depletion of T-cells with 3 – 4 Log10 [50].
9. Peripheral blood derived stem cells
The PB derived SC transplants are characterized by: a) less invasive cell collection; b) lack of the
risks of general anesthesia; c) rapid hematopoietic reconstruction; d) low harvest volume (200 –
300 mL), and e) inferior transplant-related morbidity. Thus, the number of patients treated by
PB derived SCs is ever increasing, especially in autologous transplant setting [6–8, 48–51].
Figure 4. Stem cell harvesting from peripheral blood
In steady state hematopoiesis SCs, that is CD34+ cells are in very low proportion (0.01% to 0.1%
compared to MNCs) in PB, but they can be mobilized from BM. Allogeneic donors are given
rHuG-CSF 5 (10 μg/kgbm per day). The count of CD34+ cells in the circulation begins to rise
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after 3rd day, and peaks on the 5th day of rHuG-CSF administration. In autologous setting,
patients are given higher rHuG-CSF dose (12-16 μg/kgbm or more daily) combined with
chemotherapy [8, 48–51].
In allogeneic setting, the first SC collection is performed typically on the 5th day (Figure 4.).
The optimized timing of an autologous SC harvesting is more complex and controversial. The
leukocyte count commonly does not correlate with the circulating CD34+ number. The count
of circulating CD34+ cells evidently correlate with the superior CD34+ yield in harvest.
Generally, at PB CD34+ count ≅ 10/μL, expected SC yield ≅ 1x106 per kgbm. It is also presented
that for a CD34+ ≥ 20-40/μL of PB the possibility of the CD34+ ≥ 2.5x106 per kgbm is 15% using
one standard apheresis, and 60% after one large-volume SC harvesting [6–8, 49].
The target CD34+ cells should be 330x106 per unit or ≥ 2-4x106/kgbm of the recipient in order
to expect successful transplant. Recent data support a benefit associated with greater CD34+
yield (≥ 5x106/kgbm) compared to the minimum required cell quantity for engraftment (≥ 1 x
106/kgbm) in autologous setting [20]. Finally, results obtained in our SC transplant center
confirmed that large-volume apheresis is efficient (CD34+ ≥ 5x106/kgbm) if the circulating
CD34+ count was around 40-60/μL after mobilizing regiment [8].
10. Umbilical cord blood derived stem cells
Patient's request for SCs have only in ≤ 30% (related) and ≤ 85% (unrelated) possibility of
finding an adult allogeneic donor [20]. Because of the limited availability of donors, attention
has turned to alternative sources of HLA-typed SCs. In recent years, UCB has emerged as a
feasible alternative source of transplantable CD34+ cells for allogeneic transplant, mainly in
patients who lack HLA-matched donors of BM or PB derived SCs [9–1 2].
SCs obtained from the UCB immediately after birth are usually referred to as neonatal SCs.
These cells are less mature than those in BM. The advantage of the use of UCB is painless and
non–invasive collection. UCB has advantage that – despite its high content of immune cells –
it does not produce severe GvHD. Precisely, the "naive" nature of UCB lymphocytes permits
the use of partly HLA-mismatched grafts without higher risk for severe GvHD relative to BM
transplant from a full matched unrelated donor. Thus, UCB grafts do not need to be as
"rigorously" matched to a recipient as BM or PB grafts [10–12].
On the contrary, the major disadvantage of this cell source is the limited number of SCs. UCB
volume is typically 80 – 200 mL, with a TNC count ≈1x109 and approximately CD34+ count
≈3x106 per unit. Thus, UCB is an accepted cell source for pediatric patients and for whom a
matched unrelated BM or PB cell donor is unavailable. However, a higher risk of graft failure
was noticed in children weighing ≥ 45 kg. Since the number of SCs in UCB is limited and the
collection can occur only in a single occasion – its use in adult patients can be more problematic.
Finally, since SCs in the UCB are "more primitive", the engraftment process takes longer with
UCB, leaving the patient vulnerable to posttransplant infections or bleeding. However, "more
primitive" SCs in UCB have the potential to give rise to non-hematopoietic cells (myocardial,
neural and endothelial cells, etc) by transdifferentiation [2, 9–12].
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11. Stem cell cryopreservation practice
Efficient transplant program requires both, high-quality harvesting and cryopreservation
techniques for obtaining adequate yield and recovery of the SCs. In practice, SC cryopreser‐
vation consists of the following steps: a) aspirate processing; b) equilibration (cell exposure to
cryoprotective agent) and freezing; c) storage at temperature –80±5°C (mechanical freezer), at
–140±5°C (mechanical freezer or steam of nitrogen) or at -196°C (liquid nitrogen); and d) cell
thawing in a water bath at 37±3°C. There are several cryopreservation protocols, using
primarily DMSO in autologous plasma. The optimal cooling velocity in controlled-rate
cryopreservation setting is –1°C. The transition from liquid to solid phase is also critical period
– because of released fusion heat – since a significant reduction in cell recovery and viability
has been observed when this period is prolonged. The compensation of the released fusion
heat is required, using elevated cooling rate (–2 °C per minute) during transition period.
Finally, there is data showing that uncontrolled-rate freezing is also useful in SC cryopreser‐
vation [48–52].
Cryopreserved SCs are thawed rapidly in a water bath at 38±2°C at the patient's bedside and
infused immediately through a central vein catheter. Generally, patients tolerate the infusion
of unprocessed SCs well, with no side effects. The grade of the potential reinfusion−related
toxicity is associated with total DMSO quantity in the thawed cell concentrate. Alternatively,
cryoprotectant can be removed by washing after thawing, but this procedure results in
substantial cell loss.
12. Conventional stem cell transplants – A synopsis of the clinical practice
Generally, SC transplants include the use of high-dose chemotherapy in order to obtain disease
eradication and (re)infusion (allogeneic transplant or autologous SC support) of cells collected
to get hematopoietic and clinical renewal. SC transplant with reduced-intensity conditioning
(RIC) can be offered to patients who are disqualified for high-dose conditioning because of
their age or comorbidities. Malignant hematological diseases and some immune-mediated dis‐
orders (Table 1) are the most common indication of this therapeutic approach using SCs [2, 50].
The efficacy of transplants depends on the type of disease, its stage and sensitivity for
chemotherapy, patients' age and general condition, as well as degree of the HLA-matching. In
general, survival rates are around 30 – 60% for otherwise fatal diseases. Details of the SC clinical
use – that is optimized treatment timing and efficacy, peritransplant complications, etc. – of
the transplants in presented hematological disorders will not discussed in this paper.
Briefly, autoimmune diseases, which do not respond to standard immunosuppression, could
benefit from immunoablative therapy. The idea of treatment of immune-mediated disorders
(e.g. multiple sclerosis) by autologous SC transplant is based on the hypothesis that immu‐
noablative treatment can destroy the patients "anti-self-lymphocytes" (i.e. an "immune-
resetting" process). The beneficial immunomodulating effect of allogeneic SC transplant in
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therapy of hematological malignancies has long been known, but only recently have systems
been developed to separate the GvL effect from GvHD. Using donor-specific lymphocytes, the
best results were obtained in chronic myelogenous leukemia. Moderate successes have been
reported in relapsing acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma
and some responses were obtained for acute lymphoid leukemia [2, 8, 50].
BM malignant or dysplastic disorders
Leukemias
Hodgkin's and non-Hodgkin's lymphoma
Multiple myeloma
Myelodysplastic/myeloproliferative disorders
Benign immune mediated disorders
Severe combined immunodeficiency disease
Marrow failure syndromes
Severe aplastic anemia
Autoimmune disorders
Thalassemia
Congenital Immune deficiencies
Solid tumors
Breast cancer
Ovarian cancer
Testicular cancer
Wilm's tumor
Neuroblastoma
Rhabdomyosarcoma
Ewing sarcoma
Table 1. Current indications and relative suggestions for SC transplant
Although SC transplant-related mortality and morbidity have reduced, SC transplants
continue to pose numerous potential complications. The most frequent complications are even
now engrafting failure, virus or opportunistic infections and acute or chronic GvHD. Less toxic
transplants, in the form of non-myeloablative conditioning regimens, are being actively
investigated, with the promise of expanding indications for allogeneic transplant. In addition,
SC transplant with RIC can be offered to patients who are disqualified for high-dose condi‐
tioning because of their age or comorbidities. A careful proactive assessment to identify, treat,
and, hopefully, prevent adverse events is essential to a successful transplant [2].
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We have previously analyzed our results of PB vs. BM derived SC transplants based on the
hematopoietic reconstitution. Transplants were used for the treatment of patients with severe
aplastic anemia, acute lymphoblastic leukemia, acute non–lymphoblastic leukemia, chronic
myeloid leukemia, multiple myeloma, Hodgkin's and non–Hodgkin's lymphoma, breast and
ovarian cancer, extragonadal non–seminal germ cell tumor, and severe multiple sclerosis. The
CD34+ yields for allogeneic and autologous transplants were eminent: 16.7±9.8 × 106/kgbm and
11.8±6.1 × 106/kgbm, respectively [8, 26, 27]. A typical histogram with high–level of the
CD34+ ratio in obtained PB harvest is presented in Figure 5.
Figure 5. The ratio of the CD45/CD34+ cells in peripheral blood harvest
For autologous SC transplants, the use of the best freezing process and choice of the most
appropriate cryoprotective agent is required (optimized cryobiosystem). Nowadays a variety
of protocols are used in blood–derived cell freezing practice. Generally, microprocessor–
controlled (controlled–rate) freezing is more efficient than uncontrolled–rate (without
programmed cooling) procedure due to better cell recovery. Our earlier results obtained for
cryopreserved bone marrow cells and peripheral blood mononuclear cells were in agreement
with these findings [8, 52]. These results imply a different "cryobiological request" of MRA
cells in comparison with the mature progenitors. Moreover, our clinical studies showed that
therapeutic use of the SCs – cryopreserved by our own controlled-rate system resulted with
high cell recovery (91%) and rapid posttransplant hematopoietic reconstitution – on the 11th
day in average [2, 8].
We have also investigated SC–harvesting protocols with optimized cell source, collection time–
point and processed blood volume, CD34–threshold dose (calculed by ideal body mass), as
well as immature (CD34+/CD33–, CD34+/CD38–, CD34+/DR–, CD34+/CD90+) vs. mature (CD34+/
CD33+, CD34+/CD38+, CD34+/DR+, CD34+/CD90–) CD34–subset ratio in harvest [8, 26, 28, 50].
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Several data related to our immature vs. mature CD34–subset investigations of cells collected
from different sources are presented in Table 2.
PB–SCs I PB–SCs II BM–SCs
CD34 PE / CD90 FITC [%] 1,72±1,47 1,25±0,82 2,72±2,06
CD34 PE / CD38 FITC [%] 2,02±1,18 2,02±1,18 2,3±1,16
CD34 PE / HLA–DR FITC [%] 2,01±0,92 2,0±0,92 2,0±0,88
CD34 PE / CD33 FITC [%] 1,90±1,23 1,9±1,23 2,75±1,12
PB–SCs I = stem cell collected from peripheral blood after mobilization with chemotherapy and rHuG–CSF; PB–SCs II =
stem cell collected from peripheral blood after mobilization with rHuG–CSF alone; BM–SCs = stem cell collected from
bone marrow.
Table 2. Ratio of CD34 cell markers using double staining
Finally, we found that the use of large volume vs. conventional (repetitive) apheresis resulted
in improved CD34+ yield and viability (7–AAD flow cytometric assay) [2, 8, 50]. The harvesting
of higher ratio of immature vs. mature CD34–subsets correlated with BM repopulation ability
(complete and long–term engraftment) and rapid hematopoietic reconstitution, as well as
superior organ repair or SC regenerative potential.
SCs are considered optimal targets for gene transduction due to their ability to renew them‐
selves and differentiate into progeny cells and generate a self-perpetuating cell population that
contains the transduced gene for the lifetime of the patient. Specific diseases that could be
candidates for SC gene therapy include thalassemia, sickle cell anemia, Fanconi anemia, severe
combined immune deficiency secondary to adenosine deaminase deficiency or purine
nucleoside phosphorylase deficiency, chronic granulomatous disease, leukocyte adhesion
deficiency, Gaucher's disease, and a variety of other metabolic/storage deficiencies. UCB
derived SCs potentially could be used to correct genetic deficiencies at birth after successful
gene transduction and autologous transplant [2, 50].
13. Stem cells in regenerative medicine – A rapid consideration
Cardiac repair following SC application.The occurrence of heart failure following acute
myocardial infarction – during the hospital stay and during the next few months or years – is
high (up to 50%). Patients' mortality with heart failure after infarction is also considerable. The
left ventricle dilatation occurs in even approximately one third of the patients, reperfused
effectively with primary angioplasty. The incidence of heart failure after infarction has
increased and mortality decreased with better reperfusion therapy [2, 3, 28]. Consequently, it
is imperative to develop a curative approach to prevent of myocardium remodeling. The SC
therapy is a new and promising manner of an infarcted heart healing.
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It is generally accepted that adult SCs from different tissues may transdifferentiate in special
situations into cardiomyocytes or endothelial cells. In addition, the presence of an important
quantity of cardiac cells is confirmed in proliferative state in peri-infarction region. The first
source of these "regenerative cells" is maybe cardiac SCs – which are in the inactive stage in
intact (undamaged) myocardium – but following infarction they differentiate into cardiomyo‐
cytes, smooth muscle cells and endothelial cells [2, 3]. The next discovery is that for the period
of infarction, myocardial ischemia initiates release of some cytokines, growth-factors and
chemokines – which induce SC mobilization from other niches and their homing into the
damaged myocardium. The knowledge of these processes is important because the treatment
efficacy depends on artificial ex vivo and/or in vivo intensification of some "steps" in order to
make regenerative process more beneficial.
The exact mechanism by which SCs create a protective effect resulting in tissue/organ repair
and heart function improvement is also a matter of debate. A number of possible mechanisms
have been proposed: a) SC transdifferentiation into cells of other lineages (cardiomyocytes or
endothelial cells) resulting in formation of new tissue; b) mobilization of tissue specific SCs
from the BM that home to the damaged tissue and participate in tissue regeneration; c) fusion
of the SCs with cells of the target tissue giving rise to new cells; and d) creation of a milieu
(perhaps by releasing growth factors) that enhances regeneration of endogenous cells [2, 3, 50].
At present, BM is the most frequent source of cells used for clinical cardiac repair. It contains
a complex mixture of progenitor cells – including SCs; so-called side population (SP) cells,
which account for most if not all long-term self-renewal and reconstitute the full panoply of
hematopoietic lineages after single-cell grafting; a subset of mesenchymal or stromal cells
(MSCs), which are already defined; multipotent adult non-hematopoietic progenitor cells
(MAPCs – for example, VSEL cells), which can differentiate into all possible lineages, and a
fraction of TCSC discovered recently by Ratajczak et coworkers [2, 38–44]. These TCSCs
circulate at the highest level and thus accumulate in BM during rapid body growth and become
a reserve pool of SCs for tissue/organ regeneration. They are chemo-attracted from PB to
injured organs by signaling proteins, such as stromal cell-derived factor-1, which become
highly expressed in damaged heart tissue. For therapeutic purposes, marrow is aspirated, the
entire MNC fraction is obtained – a mixed combination of mentioned cells – or specific
subpopulations are purified and isolated cells are injected into the heart without need of further
ex vivo manipulation/expansion.
In conclusion, current challenges for cell-based therapy in cardiac repair include identifying
the origins of the novel cardiac SCs found inside heart, pinpointing biologically active cells
from BM and other cell populations, optimizing cell mobilization and homing, increase of
survival of grafted SCs, and exploiting cell therapy as a platform for secretor signals. Thus, we
need a lot of basic research and randomized clinical trials to define the exact role of this
probably revolutionary therapy for ischemic heart disease.
Application of SCs for liver and pancreas regeneration. The growing donor organ shortage
requires consideration of alternative emerging technologies. Regenerative medicine may offer
novel strategies to treat patients with end-stage or severe organ failure.
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The final purpose of SC therapy, organ repopulation strategies and tissue engineering is
to regenerate tissues/organs or to produce new grafts/organs for transplant. With the ex‐
pansion  of  complete  organ  "decellularization"  methods  the  equation  of  organ  shortage
could  be  radically  altered  in  the  future.  Decellularized  organs  provide  the  ideal  trans‐
plantable platform with all  the essential microstructure and extra-cellular signals for cell
connection (homing), transdifferentiation, tissue vascularization, etc. Novel systems to re-
engineer organs may have key connotations for the fields of regenerative biology and ul‐
timately organ transplant [2, 50].
Currently available β-cell replacement therapies for patients with Type 1 diabetes (T1D),
including islet and pancreas transplant, are largely successful in restoring normal glucose
metabolism. However, there are data concerning the use of SCs to generate β-cells for islet
transplant, indicating the need for improved protocols for their derivation and full maturation.
Researchers also considered evidence indicating that adult SCs may affect islet transplant by
improving the viability of engrafted islets and controlling immune-related reactions to islet
antigens. A novel SC-based applications or regeneration-type approaches include stimulation
of endogenous regenerative mechanisms or inducing reprogramming of non-β cells into β
cells. Because these strategies would finally generate allogeneic or syngeneic β cells, the control
of alloimmunity or autoimmunity in addition to replacing lost β cells will be of the greatest
importance [2, 50].
For the SC treatment of our patients with liver failure (n = 8) and T1D (n = 4), cells were
harvested from PB following mobilization (rHuG-CSF 10μg/day; 5 days). The mean volume
of processed blood was 15.2±1.6 L (ratio: 12.8 – 18.4 L). The total count of MNC and CD34+
collected cells were 6.4±3.1x09 and 1.6±08x107, respectively. Cells were applied after immuno‐
magnetic selection and ex vivo transdifferentiation and expansion across catheter [2, 50].
The use of SCs in neurology/neurosurgery. Alzheimer's, Parkinson's and Huntington's
diseases, amyotrophic lateral sclerosis (ALS), and Friedreich's ataxia are the most common
human neurodegenerative diseases – pathologically characterized by a progressive and
specific loss of certain neuronal populations. Currently there are no effective clinical therapies
for many of these diseases. The recently acquired ability to reprogram human adult somatic
cells to "induced pluripotent SCs" (iPSCs) in culture may provide a powerful tool for in vitro
neurodegenerative disease modeling and an unlimited source for cell replacement therapy.
Reprogramming of somatic cells into iPSCs ushered in a new era of regenerative medicine.
Human iPSCs give potent new approaches for disease modeling, drug testing, developmental
studies, and therapeutic applications.
We earlier largely described the specific therapeutic actions and clinical use of SCs in neurol‐
ogy/neurosurgery [2]. Cerebral tumors, stroke, neurodegenerative diseases, brain and spinal
injuries are used as examples with different limitations and possibilities to be approached with
adult SC and/or different regenerative treatments. It is clear, that despite a spectrum of
successful approaches, there are current limitations in this field of therapeutic interventions,
which makes the research more intriguing and opens the new avenues for the development
of novel concepts, their future prove, and possible application.
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Finally, in our center SC are applied the first time in the treatment of ALS female patients
(intratecal application of non-manipulated BM derived cells; two repeated treatments) and
another female patient after brain infarction (intra-arterial cell injection using percutaneous
catheter). Logically, preliminary or particularly definitive conclusions can only be drawn from
larger, randomized, controlled clinical trials.
14. The treatment of large myocardial infarction by intracoronary applied
rHuG-CSF facilitated BM derived SCs – Our experience
14.1. Introduction
Intracoronary autologous, BM derived SC transplant for the treatment of myocardial infarction
went through the three important steps during the last decade. In the first step, small non-
randomized trials of Strauer [53] and TOPCARE study [54], established the basic methodology
of SC harvesting, cell processing and intracoronary delivery and confirmed the safety and
regenerative potential of SCs for the improvement of myocardial viability and function after
infarction.
The next step representing two landmark studies has brought controversial results. The
REPAIR-AMI [55] has showed that intracoronary delivery of BM derived SCs led to the
improvement of six months global ejection fraction and lowers the major cardiac adverse
events. On the contrary, the ASTAMI trial [56] has failed to prove any benefit of early intra‐
coronary application of BM derived SCs to the global ejection fraction and left ventricle
remodeling measured by magnetic resonance imaging at baseline and after four months of
anterior infarction. However, those studies suggested several important issues. The first of all
were that choice of patients with more severe damaged myocardium and the delayed SC
delivery for at least five days after infarction resulted to better results of SC regenerative
capacity. The second key conclusion is that SC processing process might be essential for
successful SC therapy after myocardial infarction.
In the third step, two relatively large randomized studies tried to define the efficacy of different
SC population for treatment of myocardial infarction. The REGENT study [57] used selection
of CD34+/CD-CXC4+ cells, and the HEBE trial [58] examine selection of PB derived MNCs and
compare the results with two control groups, non-selected BM origin MNCs and controls.
These trials didn't show any usefulness of cell selection and suggested again that patients with
more damaged myocardium had better improvement with intracoronary SC delivery. On the
other hand, our study has showed that there is a limit for the amount of myocardial necrosis
in which we can achieve improvement of myocardial function after intracoronary SC delivery
and the patients with the huge loss of myocardium has no any benefit from the cell therapy
[26–28]. However, improvement of global and regional left ventricle function was modest and
faraway from the expected in all studies. The next steps in SC therapy are ex vivo expansion of
the number and regenerative capacity of harvested SCs, in vivo facilitation of that, and
improvement of methods of SC delivery.
Stem Cell Biology in Normal Life and Diseases126
In our Center for regenerative medicine, total of 60 patients were treated by non-manip‐
ulated or ex vivo  cytokine stimulated BM derived cells (collected in steady state hemato‐
poiesis or after priming of the marrow). Cells were applied across percutaneous catheter
intracoronarly  or  directly  into  the  myocardium (transpericardial  approach).  In  the  most
recent  stage,  we  investigated  the  effects  of  rHuG-CSF  facilitated  BM  (primed  BM)  SC
therapy on improvement of  the global  and regional  function of  left  ventricle  after  large
myocardial infarction.
14.2. Methodology
The main inclusion criteria for the enrollment in the study are: patients with the first ST
segment elevation myocardial infarction; age younger than 71 years old; successful percuta‐
neous coronary intervention on the infarction artery inside the 24 hours from the onset of pain
and with the left ventricle ejection fraction lower than 41% at the fifth day estimated by the
transthoracic echocardiography. The main exclusion criteria are the presence of other serious
illness, any pre-infarction significant damage of the heart, allergy to aspirin and resistance to
clopidogrel, and the presence of the symptoms and signs of heart failure five days after
infarction. The local Ethical Committee approved the study and all patients were given written
informed consent.
Pre-transplant examination. At the fifth day of infarction, global and regional left ventricle
systolic function together with the end-diastolic and end-systolic volumes are measured by
the transthoracic echocardiography. Infarction size is estimated by the Technetium-sestamibi
myocardial scintigraphy between the 5-8 days from the infarction.
Stem cell harvesting and application. The day before BM harvest, patients receive 5 – 10 μg/
kgbm of rHuG-CSF. Between 7 – 12 days from the infarction in the general anesthesia 300 mL
of the BM is harvested from the posterior iliac crests. After that BM was filtered and processed
to the final volume of 30 – 50 mL of concentrated mono-nuclear cell suspension. Boluses of 10
mL are injected through the diagnostic catheter into the infarction related coronary artery.
Patients with rHuG-CSF facilitated SC therapy received 18.4x108 of MNCs and patients without
rHuG-CSF received 7.9x108 of the MNCs.
Control groups. There are two control groups with the same inclusion and exclusion criteria.
The first are patients who did not submit to any SC procedure. And the second represents the
patients who were treated with the autologous intracoronary, BM derived SC therapy without
rHuG-CSF.
The follow-up.  Clinical  examination  is  scheduled for  the  one,  fourth  and sixth  months
after infarction and every 6 months after that.  Echocardiography measurement of global
and left ventricle ejection fraction and volumes is planned after 4 months and every year
after  infarction.  Myocardial  scintigraphy is  planned after  4  months  and after  two years
from the infarction.
End points. The main end points are comparison of the 4 months and 2 years change in left
ventricle ejection fraction, volumes and infarction size between three groups.
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14.3. Results
The baseline characteristics of three groups of patients were similar except that control group
were slightly older than patients in both SC groups and have more often multivessel disease.
Gender and risk factors distribution were similar between groups. There is also no difference
in ischemic time in three groups. Baseline global left ventricle ejection fraction and infarction
size were similar in all three groups. However, both end-diastolic and end-systolic cardiac
indices were lower in patients with rHuG-CSF facilitated SC therapy.
After 4 months left ventricle ejection fraction has improved in group of patients treated with
SCs and in control group but did not reach statistical significance in the group treated with
rHuG-CSF facilitated SC therapy because of small number of patients in that group (Table 1).
Infarction size has the same pattern (Table 3). End-diastolic and end-systolic volumes increased
in all groups but also did not get to significant statistical difference in the rHuG-CSF facilitated
SC group.
Parameters
SC therapy in
AMI
n=19
G-CSF facilitated SC
therapy in AMI
n=5
Control group
n=17 p
Infarction size at baseline
LV%±SD 28,4±11,3 35,6±8,0 31,4±12,8 ns
Infarction size after 6 months
LV%±SD 25.2±12.6 25.2±8.6 27.9±10.7 ns
p 0.001 0.068 0.001
LVEF at baseline
% ± SD 32,9±4,1 36,4±3,0 34,3±5,2 ns
LVEF after 4 months
% ± SD 37,0±9,0 43,8±3,0 36,9±8,2 0,01
p 0.004 0.313 0.004
EDVCI at baseline
ml/m2 ± SD 68,3±11,3 46,1±10,0 67,8±17,6 0,01
EDVCI after 4 months
ml/m2 ± SD 75,7±15,7 54,3±6,1 73,8±20,4 0,053
p 0.024 0.161 0.004
ESVCI at baseline
ml/m2 ± SD 44,8±9,8 28,0±4,4 45,0±15,1 0.02
ESVCI at 4 months
ml/m2 ± SD 47,8±14,3 30,3±2,6 47,5±17,6 0,07
p 0.001 0.142 0.002
Table 3. Infarction size end left ventricle systolic function and volumes at baseline and after 4 months.
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Difference between baseline and 4-months infarction size is significant only in patients with
rHuG-CSF facilitated SC therapy (Figure 6). There was no significant difference between the
change of LVEF at baseline and after 4 months (Figure 6).
Figure 6. Change in infarction size between baseline and 4-months among three groups of patients
Figure 7. Change in left ventricle ejection fraction: baseline vs. 4-months among three groups of patients
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15. Conclusion
Our preliminary results have shown that rHuG-CSF facilitated autologous, intracoronary SC
transfer was safe; between two-three times higher number of MNCs were given and there was
a trend toward larger increase of 4-months ejection fraction and greater decrease of the
infarction size than the control groups. Any procedure that increases the left ventricle ejection
fraction for more than 5% after a several months follow-up would be of great clinical and
economic value. Autologous BM derived, intracoronary SC transfer in the second week of large
myocardial infarction very probably improved the global left ventricle ejection fraction by 3 –
5% although results of the published trial are controversial. Granulocyte colony stimulating
factor given alone for several days after myocardial infarction did not improve significantly
global ejection fraction in the several trials, but it seems that its early application in patients
with larger infarction could be useful. Further investigation is needed for the justification of
rHuG-CSF facilitated, BM derived SC therapy in the early phase of acute ST elevation myo‐
cardial infarction.
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